A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer

In a pancreatic cancer model, a DNA hypomethylating drug increases tumor-infiltrating effector T cells, increases a subset of M2 macrophages, and significantly prolongs survival in combination with immune checkpoint inhibitors. Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer that has proven refractory to immunotherapy. Previously, treatment with the DNA hypomethylating drug decitabine (5-aza-dC; DAC) extended survival in the KPC-Brca1 mouse model of PDAC. Here we investigated the effects of DAC in the original KPC model and tested combination therapy with DAC followed by immune checkpoint inhibitors (ICI). Four protocols were tested: PBS vehicle, DAC, ICI (anti-PD-1 or anti-VISTA), and DAC followed by ICI. For each single-agent and combination treatment, tumor growth was measured by serial ultrasound, tumor-infiltrating lymphoid and myeloid cells were characterized, and overall survival was assessed. Single-agent DAC led to increased CD4+ and CD8+ tumor-infiltrating lymphocytes (TIL), PD1 expression, and tumor necrosis while slowing tumor growth and modestly increasing mouse survival without systemic toxicity. RNA-sequencing of DAC-treated tumors revealed increased expression of Chi3l3 (Ym1), reflecting an increase in a subset of tumor-infiltrating M2-polarized macrophages. While ICI alone had modest effects, DAC followed by either of ICI therapies additively inhibited tumor growth and prolonged mouse survival. The best results were obtained using DAC followed by anti-PD-1, which extended mean survival from 26 to 54 days (P < 0.0001). In summary, low-dose DAC inhibits tumor growth and increases both TILs and a subset of tumor-infiltrating M2-polarized macrophages in the KPC model of PDAC, and DAC followed by anti-PD-1 substantially prolongs survival. Because M2-polarized macrophages are predicted to antagonize antitumor effects, targeting these cells may be important to enhance the efficacy of combination therapy with DAC plus ICI. Significance: In a pancreatic cancer model, a DNA hypomethylating drug increases tumor-infiltrating effector T cells, increases a subset of M2 macrophages, and significantly prolongs survival in combination with immune checkpoint inhibitors. See related commentary by Nephew, p. 4610

[1]  R. Fields,et al.  Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies , 2019, Science Translational Medicine.

[2]  C. Iacobuzio-Donahue,et al.  Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.

[3]  B. El-Rayes,et al.  Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions , 2018, Journal of Gastrointestinal Cancer.

[4]  A. Ferguson-Smith,et al.  Identification, Characterization, and Heritability of Murine Metastable Epialleles: Implications for Non-genetic Inheritance , 2018, Cell.

[5]  A. Welm,et al.  Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth , 2018, Oncoimmunology.

[6]  Asha Nair,et al.  Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes , 2018, Nature Communications.

[7]  C. Zahnow,et al.  Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden , 2017, Proceedings of the National Academy of Sciences.

[8]  C. Zahnow,et al.  Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer , 2017, Cell.

[9]  Chunsheng Zhang,et al.  Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. , 2017, Cancer cell.

[10]  A. Maitra,et al.  The role of stromal cancer-associated fibroblasts in pancreatic cancer , 2017, Journal of Hematology & Oncology.

[11]  T. Oyama,et al.  Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages , 2016, Oncotarget.

[12]  W. Ge,et al.  Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients , 2016, Oncotarget.

[13]  B. Stanger,et al.  Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer , 2016, Clinical Cancer Research.

[14]  V. Ellenrieder,et al.  Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? , 2016, Gut.

[15]  Michael C. Ostrowski,et al.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer , 2016, Gut.

[16]  A. Maitra,et al.  Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma , 2016, Scientific Reports.

[17]  S. Pandol,et al.  Macrophages and pancreatic ductal adenocarcinoma. , 2016, Cancer letters.

[18]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[19]  Michael C. Ostrowski,et al.  Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia1 , 2016, Neoplasia.

[20]  M. Pasca di Magliano,et al.  Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer , 2016, Gut.

[21]  Christopher Malcuit,et al.  Macrophage‐Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, Proliferation, and Migration Via a CD44‐Dependent Mechanism , 2016, Journal of cellular biochemistry.

[22]  A. Biankin,et al.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma , 2016, Cancer cell.

[23]  Sarah I. Alothman,et al.  Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. , 2016, Gastroenterology.

[24]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[25]  A. Dear.  Epigenetic Modulators and the New Immunotherapies. , 2016, The New England journal of medicine.

[26]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[27]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[28]  Halli E. Miller,et al.  Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses , 2015, Proceedings of the National Academy of Sciences.

[29]  K. Rothamel,et al.  Gene Expression during the Generation and Activation of Mouse Neutrophils: Implication of Novel Functional and Regulatory Pathways , 2014, PloS one.

[30]  J. Liu,et al.  Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity , 2014, Proceedings of the National Academy of Sciences.

[31]  Lieping Chen,et al.  Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity. , 2014, The Journal of clinical investigation.

[32]  D. Fearon.  The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance , 2014, Cancer Immunology Research.

[33]  P. Greenberg,et al.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity , 2014, Gut.

[34]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[35]  Charles C. Kim,et al.  Beyond the transcriptome: completion of act one of the Immunological Genome Project. , 2013, Current opinion in immunology.

[36]  C. Jacobi,et al.  Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[37]  S. Gordon,et al.  Tissue macrophage heterogeneity: issues and prospects , 2013, Seminars in Immunopathology.

[38]  Ting Gong,et al.  DeconRNASeq: a statistical framework for deconvolution of heterogeneous tissue samples based on mRNA-Seq data , 2013, Bioinform..

[39]  B. Tycko,et al.  Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. , 2013, Cancer research.

[40]  S. Goerdt,et al.  The CD20 homolog Ms4a8a integrates pro‐ and anti‐inflammatory signals in novel M2‐like macrophages and is expressed in parasite infection , 2012, European journal of immunology.

[41]  S. Goerdt,et al.  Differentiation and gene expression profile of tumor-associated macrophages. , 2012, Seminars in cancer biology.

[42]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[43]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[44]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[45]  Yuan Ji,et al.  Reduced levels of p15INK4b, p16INK4a, p21cip1 and p27kip1 in pancreatic carcinoma , 2012, Molecular medicine reports.

[46]  Lieping Chen,et al.  Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models , 2011, The Journal of Immunology.

[47]  M. Willart,et al.  Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice. , 2011, American journal of respiratory and critical care medicine.

[48]  David C. Gondek,et al.  VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.

[49]  A. Mackensen,et al.  Suppression of T-cell responses by tumor metabolites , 2011, Cancer Immunology, Immunotherapy.

[50]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[51]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[52]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[53]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[54]  P. Loke.  Faculty Opinions recommendation of Alternatively activated macrophage-derived RELM-{alpha} is a negative regulator of type 2 inflammation in the lung. , 2009 .

[55]  A. Murphy,et al.  Alternatively activated macrophage-derived RELM-α is a negative regulator of type 2 inflammation in the lung , 2009, The Journal of experimental medicine.

[56]  D. Hume,et al.  Gpnmb Is Induced in Macrophages by IFN-γ and Lipopolysaccharide and Acts as a Feedback Regulator of Proinflammatory Responses1 , 2007, The Journal of Immunology.

[57]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[58]  Paolo Serafini,et al.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. , 2006, The Journal of clinical investigation.

[59]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[60]  Judith E. Allen,et al.  Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. , 2003, Immunology letters.

[61]  John S. Welch,et al.  TH2 Cytokines and Allergic Challenge Induce Ym1 Expression in Macrophages by a STAT6-dependent Mechanism* , 2002, The Journal of Biological Chemistry.

[62]  M. Wills-Karp.  Faculty Opinions recommendation of Expression of the Ym2 lectin-binding protein is dependent on interleukin (IL)-4 and IL-13 signal transduction: identification of a novel allergy-associated protein. , 2001 .

[63]  J. Liao,et al.  Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. , 2001, Cancer research.